AMARIN CORP PLC\UK Direct Operating Costs
AMARIN CORP PLC\UK (AMRN) reported Direct Operating Costs of $20.48 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DirectOperatingCosts · last filed 2015-03-03
- AMARIN CORP PLC\UK direct operating costs for the quarter ending 2014-12-31 was $5.85M, a 43.16% increase year-over-year.
- AMARIN CORP PLC\UK direct operating costs for the quarter ending 2014-09-30 was $5.37M, a 47.91% increase year-over-year.
- AMARIN CORP PLC\UK direct operating costs for the quarter ending 2014-06-30 was $5.03M, a 137.36% increase year-over-year.
- AMARIN CORP PLC\UK direct operating costs for the quarter ending 2014-03-31 was $4.25M, a 56.74% increase year-over-year.
- AMARIN CORP PLC\UK direct operating costs for fiscal 2014 was $20.48M, a 63.37% increase from fiscal 2013.
- AMARIN CORP PLC\UK direct operating costs for fiscal 2013 was $12.54M.
| Period end | Direct Operating Costs 3 month | Direct Operating Costs 6 month | Direct Operating Costs 9 month | Direct Operating Costs 12 month |
|---|---|---|---|---|
| 2014-12-31 | $5.85M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | $11.21M derived: sum of 2 quarters · filed 2015-03-03 | $16.24M derived: sum of 3 quarters · filed 2015-03-03 | $20.48M 10-K · filed 2015-03-03 |
| 2014-09-30 | $5.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $10.39M derived: sum of 2 quarters · filed 2014-11-06 | $14.64M 10-Q · filed 2014-11-06 | $18.72M derived: sum of 4 quarters · filed 2015-03-03 |
| 2014-06-30 | $5.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $9.27M 10-Q · filed 2014-08-07 | $13.36M derived: sum of 3 quarters · filed 2015-03-03 | $16.98M derived: sum of 4 quarters · filed 2015-03-03 |
| 2014-03-31 | $4.25M 10-Q · filed 2014-05-09 | $8.33M derived: sum of 2 quarters · filed 2015-03-03 | $11.96M derived: sum of 3 quarters · filed 2015-03-03 | $14.08M derived: sum of 4 quarters · filed 2015-03-03 |
| 2013-12-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | $7.71M derived: sum of 2 quarters · filed 2015-03-03 | $9.83M derived: sum of 3 quarters · filed 2015-03-03 | $12.54M 10-K · filed 2015-03-03 |
| 2013-09-30 | $3.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $5.75M derived: sum of 2 quarters · filed 2014-11-06 | $8.45M 10-Q · filed 2014-11-06 | |
| 2013-06-30 | $2.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $4.83M 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | $2.71M 10-Q · filed 2014-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |